Since triple positive HR+/HER2+ breast cancer patients tend to be less responsive to endocrine therapy[19], we propose that extensive interactions exist between the HER2 signaling pathway and the ER signaling pathways and a large body of recent literature supports this hypothesis[19–23]. The gene discussed is ERBB2; the disease is breast cancer.